Detalles de la búsqueda
1.
Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials.
Diabetes Obes Metab
; 18(11): 1093-1097, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27484021
2.
Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.
Diabetes Obes Metab
; 18(11): 1089-1092, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27486125
3.
Effect of ruboxistaurin on albuminuria and estimated GFR in people with diabetic peripheral neuropathy: results from a randomized trial.
Am J Kidney Dis
; 65(4): 634-6, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25618186
4.
Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins.
J Investig Med
; 66(3): 661-668, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29167192
5.
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Cell Metab
; 26(2): 343-352.e2, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28768173
6.
Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy.
Clin Ther
; 27(8): 1278-94, 2005 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16199253
7.
Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
Clin Ther
; 27(8): 1164-80, 2005 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16199243
8.
The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy.
Diabetes Technol Ther
; 7(3): 497-508, 2005 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15929681
9.
Performance of an Electronic Diary System for Intensive Insulin Management in Global Diabetes Clinical Trials.
Diabetes Technol Ther
; 17(8): 571-9, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25826466
10.
Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.
Diabetes Care
; 37(3): 659-65, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24198302
11.
Time-Averaged Self-Monitored Blood Glucose Values Estimate Hemoglobin A1c Outcomes in Patients With Type 1 Diabetes.
J Diabetes Sci Technol
; 12(4): 905-906, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29514508
12.
Diagnosis of diabetic peripheral neuropathy among patients with type 1 and type 2 diabetes in France, Italy, Spain, and the United Kingdom.
Prim Care Diabetes
; 1(3): 129-34, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-18632033
13.
Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials.
Diabetes Care
; 30(10): 2626-32, 2007 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17623822
14.
Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity.
Diabetes Care
; 30(10): 2619-25, 2007 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17513707
15.
A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
Diabetes Care
; 30(4): 896-902, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17392551
16.
Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.
Expert Opin Drug Saf
; 5(6): 835-45, 2006 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17044810
17.
Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy.
Muscle Nerve
; 32(5): 619-25, 2005 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16116628
Resultados
1 -
17
de 17
1
Próxima >
>>